NMN/NR and Progesterone HRT: Interaction Safety, Mechanisms, and Clinical Guidance

Why This Combination Matters for Women on HRT

Women using progesterone as part of hormone replacement therapy are increasingly adding NAD+ precursors like NMN or NR to their supplement regimens. The reasoning is straightforward: NAD+ levels decline with age, and replenishing them may support cellular energy metabolism, DNA repair, and mitochondrial function [1]. Progesterone, meanwhile, remains a standard component of combined HRT for endometrial protection in women with an intact uterus [2].

The question of safety when combining these two agents has no simple lookup in any drug interaction database. NMN and NR are classified as dietary supplements, not FDA-approved drugs, which means they are absent from standard DDI (drug-drug interaction) compendia like Lexicomp or Micromedex. This gap forces clinicians and patients to reason from first principles: pharmacokinetic pathways, pharmacodynamic overlap, and the limited human trial data available for each compound. A 2022 meta-analysis of NMN human trials (encompassing 302 participants across five RCTs) found no serious adverse events and no clinically significant changes in hepatic enzymes [3]. That safety profile provides a foundation for evaluating the combination, but it does not substitute for direct interaction studies, which have not been conducted.

Pharmacokinetic Assessment: CYP Enzymes, Pgp, and Metabolism

Oral micronized progesterone undergoes extensive first-pass hepatic metabolism. The FDA-approved label for Prometrium lists CYP3A4 as the primary metabolic enzyme, with CYP2C19 contributing to its conversion into 5-alpha and 5-beta reduced metabolites, including allopregnanolone [4]. Strong CYP3A4 inhibitors (ketoconazole, for example) can increase progesterone exposure, while inducers (rifampin, carbamazepine) can reduce it.

NMN and NR follow different metabolic routes entirely. NMN enters cells via the Slc12a8 transporter or is first converted extracellularly to NR by CD73 (ecto-5'-nucleotidase), then NR is taken up by equilibrative nucleoside transporters and phosphorylated intracellularly by nicotinamide riboside kinases (NRK1/NRK2) to regenerate NMN and then NAD+ [5]. This pathway bypasses hepatic CYP-mediated oxidation. In vitro studies on nicotinamide (a downstream metabolite of both NMN and NR) show it is primarily cleared by nicotinamide N-methyltransferase (NNMT) in the liver, producing N-methyl-nicotinamide, not by CYP enzymes [6].

No published data demonstrate that NMN or NR inhibit or induce CYP3A4, CYP2C19, or P-glycoprotein at doses used in human supplementation (250 to 1,250 mg/day for NMN; 300 to 2,000 mg/day for NR) [7]. This means progesterone plasma levels are unlikely to be altered by co-administration. The pharmacokinetic interaction risk is low.

Pharmacodynamic Overlap: The Sedation Question

The more relevant concern is pharmacodynamic. Oral micronized progesterone is well known to cause drowsiness and sedation. This effect is not from progesterone itself but from its metabolite allopregnanolone, a potent positive allosteric modulator of GABA-A receptors [8]. The Prometrium label lists somnolence among the most common adverse reactions, reported by 27% of women taking 200 mg nightly in clinical trials [4]. This is the reason clinicians prescribe oral progesterone at bedtime.

NMN and NR, by contrast, are not sedating agents. Some users anecdotally report fatigue or mild drowsiness with higher NMN doses (above 500 mg), though this has not been consistently observed in controlled trials. In the 12-week RCT by Yi et al. (2023, N=80), NMN at 600 mg and 1,200 mg daily did not produce statistically significant increases in fatigue or somnolence compared to placebo [9]. A separate NR trial (NIAGEN, 1,000 mg twice daily for 6 weeks, N=40) similarly reported no sedation signals [10].

The theoretical concern is additive: if a patient happens to be among the minority who experience NMN-related fatigue, layering that on top of progesterone's GABA-ergic sedation could amplify drowsiness. This is a class-effect caution rather than a documented interaction. Dr. Charles Brenner, who discovered NR's role as an NAD+ precursor, has stated: "NR and NMN are biosynthetically converted to NAD and do not have direct receptor-mediated pharmacology that would interact with hormonal agents" [11]. That assessment aligns with the mechanistic data.

Dose Ranges and What Human Trials Actually Show

Understanding the doses studied helps contextualize any risk assessment. For NMN, the largest published dose-escalation study (Fukamizu et al., 2022) administered 250 mg/day for 12 weeks in healthy adults (N=30) and found it safe, with significant increases in whole-blood NAD+ levels and no adverse liver or kidney effects [12]. The Yi et al. trial pushed doses to 1,200 mg/day and still reported a favorable safety profile [9].

For NR, the landmark CHROMAVITA trial (Martens et al., 2018, N=24 crossover) gave 500 mg twice daily (1,000 mg total) for 6 weeks and observed a 60% increase in NAD+ metabolites in peripheral blood mononuclear cells, with no serious adverse events [13]. Conze et al. (2019) published a safety assessment of NR at up to 2,000 mg/day, finding it "well tolerated with no evidence of hepatotoxicity" across multiple human trials [7].

For oral micronized progesterone in HRT, the standard dose is 200 mg nightly for 12 days per cycle (sequential regimen) or 100 mg nightly (continuous combined regimen), as recommended by the 2022 Hormone Therapy Position Statement from The North American Menopause Society (NAMS) [14]. The NAMS statement notes that "micronized progesterone may have a more favorable cardiovascular and breast safety profile compared with synthetic progestins," which is partly why it has become the preferred progestogen in many HRT protocols [14].

Liver Function: A Shared Monitoring Parameter

Both compounds pass through the liver and deserve hepatic monitoring when used long-term, though neither is considered hepatotoxic at standard doses. Oral progesterone's first-pass metabolism generates metabolites that are glucuronidated and excreted renally. The Prometrium label advises caution in patients with hepatic impairment and recommends against use in severe liver disease [4].

NMN and NR increase hepatic NAD+ pools, which influences sirtuin activity (particularly SIRT1 and SIRT3) and PARP-mediated DNA repair [1]. In animal models, supraphysiologic NAD+ repletion has shown hepatoprotective effects in nonalcoholic fatty liver disease, but these findings have not been confirmed in large human trials [15]. The Conze et al. safety review of NR found no ALT or AST elevations exceeding 1.5 times the upper limit of normal across pooled data [7].

For patients combining the two, a baseline hepatic panel and follow-up at 3 to 6 months is a reasonable monitoring strategy, particularly for women already on multi-drug HRT regimens or those with pre-existing liver conditions.

Timing Strategy to Minimize Any Overlap

The simplest clinical mitigation is temporal separation. Take NMN or NR in the morning (many users prefer this because NAD+ biosynthesis may influence circadian clock gene expression via SIRT1-mediated deacetylation of BMAL1 and PER2) [16]. Take oral micronized progesterone at bedtime, which is already the standard recommendation to capitalize on its sedative effect for sleep benefit.

This approach accomplishes two things. It avoids any theoretical peak-plasma overlap between NMN (Tmax approximately 1 to 2 hours post-ingestion based on pharmacokinetic data from Irie et al., 2020, N=10) [17] and progesterone (Tmax approximately 2 to 3 hours for oral micronized formulation) [4]. It also allows the allopregnanolone-mediated sedation to coincide with the sleep window rather than daytime activity.

Women using vaginal progesterone (such as Endometrin or compounded suppositories) face an even lower sedation risk, because vaginal administration largely bypasses hepatic first-pass metabolism and produces far less allopregnanolone. A crossover study by de Lignieres et al. found that vaginal progesterone produced plasma allopregnanolone levels 60 to 80% lower than the same dose given orally [18]. For women concerned about sedation overlap, vaginal progesterone is a reasonable alternative to discuss with their prescriber.

Who Should Exercise Extra Caution

Certain patient populations warrant closer attention when combining these agents. Women with hepatic impairment should consult their physician before adding NMN/NR to a progesterone-containing HRT regimen, given that both rely on hepatic processing. Women taking additional GABA-ergic agents (benzodiazepines, gabapentin, alcohol) face compounded sedation risk and should be counseled explicitly.

Women with a history of hormone-sensitive cancers should note that while NMN/NR do not have direct estrogenic or progestogenic activity, NAD+ influences cellular proliferation pathways (including CD38, PARPs, and sirtuins) that intersect with cancer biology in complex ways [19]. The 2023 Endocrine Society Clinical Practice Guideline on menopausal HRT recommends individualized risk-benefit assessment for all combination therapies in this population [20].

Patients taking medications that are strong CYP3A4 inhibitors or inducers should be aware that those drugs may alter progesterone levels independently of NMN/NR. Common examples include fluconazole (inhibitor), St. John's Wort (inducer), and grapefruit juice (inhibitor). The interaction concern in these cases is with progesterone, not with NMN or NR.

What Prescribers Should Document

For clinicians managing patients on this combination, documentation should include: the specific NAD+ precursor (NMN vs. NR, as they differ in bioavailability and transporter pathways), the daily dose, the brand or manufacturer (since supplement quality varies widely), and the progesterone formulation (oral vs. vaginal) and dose. Baseline and follow-up labs should include a hepatic panel (ALT, AST, bilirubin), and clinicians may consider monitoring serum progesterone levels at 3 months to confirm that NMN/NR supplementation has not altered expected hormonal pharmacokinetics. If progesterone levels appear unexpectedly low or high, CYP-mediated interaction should be reconsidered despite the current lack of evidence, as post-market data on NMN/NR remain limited.

Current FDA guidance classifies NMN's regulatory status as unresolved. In November 2022, the FDA excluded NMN from the definition of a dietary supplement based on its prior investigation as a new drug candidate (IND) by Metro International Biotech [21]. NR (marketed as NIAGEN by ChromaDex) retains its NDI (New Dietary Ingredient) notification status and GRAS self-affirmation. Clinicians should be aware of this regulatory distinction, as it affects product availability, quality assurance, and patient counseling.

The recommended starting dose for patients who wish to combine these agents: NMN 250 mg or NR 300 mg each morning, with oral micronized progesterone 100 to 200 mg at bedtime, reassessing at 4 to 6 weeks for any sedation complaints, sleep quality changes, or hepatic symptoms.